Nelotanserin (APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A. It was shown to be effective and well tolerated in clinical trials but development was halted in December 2008 because the substance did not meet the trial’s endpoints. Research continues on newer analogues which may potentially be more successful.
This page contains content from the copyrighted Wikipedia article "Nelotanserin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
